NCT01989949View on ClinicalTrials.gov

Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

April 30, 2013

Conditions
Normal Drug Tolerance
Interventions
DRUG

TP-434 (Eravacycline) reconstituted and administered via an IV infusion

Trial Locations (1)

06102

Center for Anti-infective Research and Development; Hartford Hospital, Hartford

All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Tetraphase Pharmaceuticals, Inc

INDUSTRY

NCT01989949 - Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women | Biotech Hunter | Biotech Hunter